PTH and osteoporosis: The determinants of bone fragility in osteoporosis and how currently approved treatments for osteoporosis augment bone strength independent of changes in BMD are still being defined.(35–37) Therefore, we evaluated the effects of antiresorptive agents and PTH on other properties of bone quality including bone microarchitecture, surface-based and biochemical markers of turnover, mineralization, crystal size, and whole bone material properties in aged estrogen deficiency OVX rats for 60 and 180 days.